Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
06/2002
06/20/2002WO2002048405A2 Non-invasive method for detecting target rna
06/20/2002WO2002048397A2 Regulation of human adenylate cyclase, type vii
06/20/2002WO2002048388A2 Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell
06/20/2002WO2002048384A2 Nucleic acid sequence 'm73791' serving as a human gene, and derivatives thereof
06/20/2002WO2002048374A1 A NOVEL POLYPEPTIDE, A HUMAN ss-GLUCOSIDURONATASE 26.29 AND THE POLYNUCLEOTIDE ENCODING THE POLYPEPTIDE
06/20/2002WO2002048373A1 A novel polypeptide, a human mitochondrial methionyl-trna transformylase 41.14 and the polynucleotide encoding the polypeptide
06/20/2002WO2002048372A2 Target enzymes
06/20/2002WO2002048370A2 Compositions and methods relating to colon specific genes and proteins
06/20/2002WO2002048369A2 Polynucleotide encoding a human potassium channel beta-subunit, k+mbeta1
06/20/2002WO2002048368A2 Proteins associated with cell growth, differentiation, and death
06/20/2002WO2002048366A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
06/20/2002WO2002048363A2 Human transporter proteins, nucleic acid molecules encoding them, and uses thereof
06/20/2002WO2002048361A2 Novel secreted proteins and their uses
06/20/2002WO2002048357A1 A novel polypeptide, a human c0p9 compound subunit 37.62 and the polynucleotide encoding the polypeptide
06/20/2002WO2002048355A1 A novel polypeptide, a human garp protein 12.98 and the polynucleotide encoding the polypeptide
06/20/2002WO2002048354A1 Tumour suppressor gene identified on chromosome 18
06/20/2002WO2002048353A2 Dna-sequences, which code for an apoptosis signal transduction protein
06/20/2002WO2002048351A2 A method for in vitro molecular evolution of protein function
06/20/2002WO2002048349A1 Polypeptide capable of binding to heparin
06/20/2002WO2002048348A1 Novel gene existing in human leukocyte antigen domain
06/20/2002WO2002048346A2 Transgenic mice containing bsmap gene disruptions
06/20/2002WO2002048345A2 Transgenic mice containing glutamate receptor (grik5) gene disruptions
06/20/2002WO2002048343A2 Transgenic mice containing adrenocorticotropin hormone receptor gene disruptions
06/20/2002WO2002048341A2 Knockout mice for a2d2 calcium ion channel subunit proteins
06/20/2002WO2002048340A2 Transgenci mice containing cashgene disruptions
06/20/2002WO2002048339A2 Transgenic mice containing kir5.1 inwardly rectifying potassium channel gene disruptions
06/20/2002WO2002048337A2 Secreted human proteins
06/20/2002WO2002048336A2 Short peptides from the 'a-region' of protein kinases which selectively modulate protein kinase activity
06/20/2002WO2002048329A2 Membrane derived caspase-3, compositions comprising the same and methods of use therefor
06/20/2002WO2002048328A2 Isolated human kinase proteins, their encoding nucleic acid molecules, and uses thereof
06/20/2002WO2002048326A2 Human caplain proteins and polynucleotides coding therefor
06/20/2002WO2002048324A1 Regulation of human ubiquitin-conjugating enzyme e2
06/20/2002WO2002048314A2 Antisense modulation of raidd expression
06/20/2002WO2002048312A2 Backbone cyclized inhibitors of heat shock proteins
06/20/2002WO2002048310A2 Methods and compositions for diagnosing and treating rheumatoid arthritis
06/20/2002WO2002048194A1 Fusion protein having the enhanced in vivo activity of erythropoietin
06/20/2002WO2002048192A2 Amidated glucagon-like peptide-1
06/20/2002WO2002048191A2 Inhibitory agents derived from specific growth factors
06/20/2002WO2002048188A1 Plasmodium aldolase polypeptides and nucleic acids
06/20/2002WO2002048186A1 A novel polypeptide-homo insulinoid growth factor conjugated protein 10.45 and polynucleotide encoding said polypeptide
06/20/2002WO2002048184A2 Glycoprotein peptide of the human herpesvirus-7 for use in particular in an elisa serologic test
06/20/2002WO2002048183A2 Compositions of peptide crystals
06/20/2002WO2002048182A2 Interferon-alpha induced gene
06/20/2002WO2002048181A1 Antibodies, peptides, analogs and uses thereof
06/20/2002WO2002048180A2 Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament
06/20/2002WO2002048173A2 Expression of a cadherin-like protein in benign prostatic hyperplasia
06/20/2002WO2002048172A2 Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
06/20/2002WO2002048168A1 Antisense modulation of tnfr1 expression
06/20/2002WO2002048157A2 Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
06/20/2002WO2002047730A2 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins
06/20/2002WO2002047728A2 Treatment of posterior capsule opacification
06/20/2002WO2002047727A1 Therapeutic agent comprising a b-subunit of a protein toxin
06/20/2002WO2002047719A2 Survical promoting ncam binding and ncam ligand biding compounds
06/20/2002WO2002047717A2 Targeted enzyme prodrug therapy
06/20/2002WO2002047716A2 Chronic treatment regimen using glucagon-like insulinotropic peptides
06/20/2002WO2002047715A2 Compositions of peptide crystals
06/20/2002WO2002047714A1 Management of the consequences of fetal programming
06/20/2002WO2002047713A2 Composition containing a mixture of growth factor for the treatment of renal injury
06/20/2002WO2002047712A2 Peptide yy and peptide yy agonists for treatment of metabolic disorders
06/20/2002WO2002047711A2 Modulators of activity of g-protein-coupled receptor kinases
06/20/2002WO2002047710A2 Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer
06/20/2002WO2002047709A2 Resistant thymidylate synthase mutants for locally treating a chemotherapy-induced mucositis and other side effects associated with chemotherapy
06/20/2002WO2002047705A2 Compositions containing an active fraction isolated from tricholoma conglobatum and methods of use
06/20/2002WO2002047671A2 Lactam compound to inhibit beta-amyloid peptide release or synthesis
06/20/2002WO2002047613A2 Immunogenic cancer peptides and uses thereof
06/20/2002WO2002047612A2 Dietary supplement compositions
06/20/2002WO2002047611A2 Cddo-compounds and combination therapies thereof
06/20/2002WO2002047540A2 Methods for inhibiting fibrosis
06/20/2002WO2002047534A2 Compositions and methods for the therapy and diagnosis of lung cancer
06/20/2002WO2002047493A2 Health promoting compositions
06/20/2002WO2002031110A3 Hematopoietic stem cell gene therapy
06/20/2002WO2002030320A3 Stimulation of thymus for vaccination development
06/20/2002WO2002028406A3 Induction of blood vessel formation by polynucleotides encoding sphingosine kinases
06/20/2002WO2002022571A3 Compounds and methods for inhibiting alpha-1 beta-1 integrins
06/20/2002WO2002022077A3 Compositions and methods for inhibition of hiv-1 infection
06/20/2002WO2002020464A3 Benzene tricarboxylic acid amides as insulin receptor activators
06/20/2002WO2002012334A3 Snake venom polypeptide zsnk1
06/20/2002WO2002011669A3 Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof
06/20/2002WO2002008393A3 Serine protease from yersinia enterocolitica
06/20/2002WO2002007740A3 Snake toxin and use thereof as a pharmaceutical
06/20/2002WO2002006190A3 Crystalline and salt forms of an hiv protease inhibitor
06/20/2002WO2002004608A3 Regulation of human oligopeptidase a-like enzyme
06/20/2002WO2002003911A8 Prevention and treatment of alzheimer's disease
06/20/2002WO2002003910A3 Antibacterial, antioxidant, immunomoduling and anticancerogenic preparation and method for using said preparation
06/20/2002WO2002000711A3 Ev-vegf nucleic acids and polypeptides and methods of use
06/20/2002WO2002000709A3 Cerebellin homologous polypeptides and therapeutic uses thereof
06/20/2002WO2001097774A3 Novel pharmaceutical composition for the topical application of water-insoluble and/or hardly water-soluble active agents
06/20/2002WO2001094613A3 Methods and compounds for influencing beta3 integrin-dependent intracellular processes
06/20/2002WO2001090152A3 Compositions and methods for the therapy and diagnosis of breast cancer
06/20/2002WO2001090139A3 A ligand for enhancing oral and cns delivery of biological agents
06/20/2002WO2001089570A3 Combination of growth hormone secretagogues and antidepressants
06/20/2002WO2001087977A3 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
06/20/2002WO2001085959A3 Regulation of human lysostaphin-like protease
06/20/2002WO2001085942A3 Cytoskeleton-associated proteins
06/20/2002WO2001085096A3 Mast cell regulation
06/20/2002WO2001083524A3 Rna metabolism proteins
06/20/2002WO2001081417A3 Use of taci as an anti-tumor agent
06/20/2002WO2001079487A3 Polydesoxyribonucleotides for inhibiting the expression of the icam-1-gene
06/20/2002WO2001077113A3 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
06/20/2002WO2001075098A3 33166, a human hydrolase-like molecule and uses thereof
1 ... 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 ... 3163